Terms: = Melanoma AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
606 results:
1. Spitz melanoma with MAP3K8::ABLIM1 rearrangement: a case report with review of the literature.
Sibira R; Vu A; Giubellino A; Murugan P
Diagn Pathol; 2024 Oct; 19(1):133. PubMed ID: 39363234
[TBL] [Abstract] [Full Text] [Related]
2. Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
Di Pietro FR; Marinelli D; Verkhovskaia S; Poti G; Falcone R; Carbone ML; Morelli MF; Zappalà AR; Di Rocco ZC; Morese R; Piesco G; Chesi P; Marchetti P; Failla CM; De Galitiis F
BMC Cancer; 2024 Oct; 24(1):1220. PubMed ID: 39354418
[TBL] [Abstract] [Full Text] [Related]
3. Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on braf Mutant melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation.
Alfei S; Zuccari G; Athanassopoulos CM; Domenicotti C; Marengo B
Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337557
[TBL] [Abstract] [Full Text] [Related]
4. Innovations in Rare Gynecologic Cancer: melanoma, Neuroendocrine, and Low-Grade Serous Ovarian.
Au-Yeung G; MacArthur E; Chan J; Ilenkovan N; Frumovitz M; Fader AN; Gourley C
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431818. PubMed ID: 39177646
[TBL] [Abstract] [Full Text] [Related]
5. Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy.
Levati L; Tabolacci C; Facchiano A; Facchiano F; Alvino E; Antonini Cappellini GC; Scala E; Bonmassar L; Caporali S; Lacal PM; Bresin A; De Galitiis F; Russo G; D'Atri S
J Exp Clin Cancer Res; 2024 Aug; 43(1):226. PubMed ID: 39143551
[TBL] [Abstract] [Full Text] [Related]
6. Clinical, dermatoscopic, histological and molecular predictive factors of distant melanoma metastasis: A systematic review and meta-analysis.
Lallas K; Kyrgidis A; Chrysostomidis A; Vakirlis E; Apalla Z; Lallas A
Crit Rev Oncol Hematol; 2024 Oct; 202():104458. PubMed ID: 39074631
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients.
Jia DD; Li T
Sci Rep; 2024 Jul; 14(1):16607. PubMed ID: 39025927
[TBL] [Abstract] [Full Text] [Related]
8. The ERK5 pathway in brafV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib.
Mondru AK; Wilkinson B; Aljasir MA; Alrumayh A; Greaves G; Emmett M; Albohairi S; Pritchard-Jones R; Cross MJ
FEBS Lett; 2024 Aug; 598(16):2011-2027. PubMed ID: 38977937
[TBL] [Abstract] [Full Text] [Related]
9. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in braf mutant melanoma.
Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T
Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma.
Lochrin SE; Cugliari MK; Yeh R; Shoushtari AN
Melanoma Res; 2024 Oct; 34(5):450-456. PubMed ID: 38953532
[TBL] [Abstract] [Full Text] [Related]
11. Interaction of DisBa01 peptide from Bothrops alternatus venom with braf melanoma receptors: Modeling and molecular docking.
Bialves TS; Bastos LL; Parra JAA; Moysés MN; Marques E; de Castro Pimenta AM; Quintela FM; Mariano DCB; Carvalho FC; de Melo-Minardi RC; Boyle RT
Int J Biol Macromol; 2024 Aug; 274(Pt 1):133283. PubMed ID: 38909731
[TBL] [Abstract] [Full Text] [Related]
12. melanoma Management: Exploring Staging, prognosis, and Treatment Innovations.
Shalata W; Attal ZG; Solomon A; Shalata S; Abu Saleh O; Tourkey L; Abu Salamah F; Alatawneh I; Yakobson A
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891988
[TBL] [Abstract] [Full Text] [Related]
13. The role of macrophage migration inhibitory factor family and CD74 in the pathogenesis of melanoma.
Tanese K; Ogata D
Exp Dermatol; 2024 Jun; 33(6):e15122. PubMed ID: 38884501
[TBL] [Abstract] [Full Text] [Related]
14. Identification of braf Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.
Wen X; Han M; Hosoya M; Toshima R; Onishi M; Fujii T; Yamaguchi S; Kato S
Anticancer Res; 2024 Jun; 44(6):2349-2358. PubMed ID: 38821628
[TBL] [Abstract] [Full Text] [Related]
15. Regorafenib in patients with pretreated advanced melanoma: a single-center case series.
Vander Mijnsbrugge AS; Cerckel J; Dirven I; Tijtgat J; Vounckx M; Claes N; Neyns B
Melanoma Res; 2024 Aug; 34(4):366-375. PubMed ID: 38801446
[TBL] [Abstract] [Full Text] [Related]
16. SIRT7 promotes mitochondrial biogenesis to render the adaptive resistance to MAPK inhibition in melanoma.
Du J; Yi X; Guo S; Wang H; Shi Q; Zhang J; Tian Y; Wang H; Zhang H; Zhang B; Gao T; Li C; Guo W; Yang Y
Biochem Biophys Res Commun; 2024 Aug; 722():150161. PubMed ID: 38797153
[TBL] [Abstract] [Full Text] [Related]
17. Review of the comparative pathological and immunohistochemical features of human and canine cutaneous melanocytic neoplasms.
Contel IJ; Fonseca-Alves CE; Ferrari HF; Laufer-Amorim R; Xavier-Júnior JCC
J Comp Pathol; 2024 May; 211():26-35. PubMed ID: 38761560
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios.
Roccuzzo G; Sarda C; Pala V; Ribero S; Quaglino P
Expert Rev Mol Diagn; 2024 May; 24(5):379-392. PubMed ID: 38738539
[TBL] [Abstract] [Full Text] [Related]
19. [Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.].
Cerro M; Maccallini MT; Russillo M
Recenti Prog Med; 2024 May; 115(5):13e-16e. PubMed ID: 38708541
[TBL] [Abstract] [Full Text] [Related]
20. Latent-Transforming Growth Factor β-Binding Protein 1/Transforming Growth Factor β1 Complex Drives Antitumoral Effects upon ERK5 Targeting in melanoma.
Tubita A; Menconi A; Lombardi Z; Tusa I; Esparís-Ogando A; Pandiella A; Gamberi T; Stecca B; Rovida E
Am J Pathol; 2024 Aug; 194(8):1581-1591. PubMed ID: 38705382
[TBL] [Abstract] [Full Text] [Related]
[Next]
